Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)-Reference-Cited by-同舟云学术

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Published:2023-05 Issue:5 Volume:83 Page:405-412
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Seifert Robert,Emmett Louise,Rowe Steven P.,Herrmann Ken,Hadaschik Boris,Calais Jeremie,Giesel Frederik L.,Reiter Robert,Maurer Tobias,Heck Matthias,Gafita Andrei,Morris Michael J.,Fanti Stefano,Weber Wolfgang A.,Hope Thomas A.,Hofman Michael S.,Fendler Wolfgang Peter,Eiber Matthias

Funder

Turun Yliopisto

Turun Yliopistollinen Keskussairaala

Publisher

Elsevier BV

Subject

Urology

Reference47 articles.

1. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study;Morris;Clin Cancer Res,2021

2. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY);Pienta;J Urol,2021

3. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial;Fendler;JAMA Oncol,2019

4. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial;Hope;JAMA Oncol,2021

5. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT;Eiber;J Nucl Med,2018

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRI and active surveillance: thoughts from across the pond;European Radiology;2024-09-12

2. The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-12

3. Development of¹⁸F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance;Journal of Nuclear Medicine;2024-09-12

4. Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy;Diagnostics;2024-09-05

5. PSMA PET/CT imaging and its application to prostate cancer treatment;Japanese Journal of Radiology;2024-09-03